Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Pediatr Blood Cancer. 2017 Oct 28;65(2):10.1002/pbc.26870. doi: 10.1002/pbc.26870

Figure 2.

Figure 2

Patritumab enhances the activity of vincristine and cyclophosphamide. Mice bearing ES-4 Ewing sarcoma xenografts were treated as described in Materials and Methods. Growth of individual tumors is presented. Tumor volumes (cm3) are plotted against time (weeks) (P, patritimab). Right panels show Kaplan-Maier Event Free survival (%); control (black), cytotoxic drug (blue), cytotoxic drug + patritumab (P; red).